Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansiet ischaeMic attack. The PERFORM Study. An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for 3-year mean duration (event driven trial).

Trial Profile

Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansiet ischaeMic attack. The PERFORM Study. An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for 3-year mean duration (event driven trial).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Aspirin (Primary) ; Terutroban sodium (Primary)
  • Indications Cardiovascular disorders; Embolism and thrombosis; Stroke; Transient ischaemic attacks
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms PERFORM
  • Most Recent Events

    • 30 May 2011 Results published in the Lancet.
    • 03 Mar 2011 New source identified and integrated (United Kingdom Clinical Research Network, 9869).
    • 29 Sep 2010 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top